Bayer Ag Sponsored ADR (BAYRY)$11.11
Market Cap: 26.89 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Bayer Ag Sponsored ADR (BAYRY).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
N/A
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
N/A
Debt/equity, N/A current ratio
Superinvestors
1
Top: Kahn Brothers Group (13.3%)
Strengths to research
No strong positive screening signals were detected from the checked-in dataset.
Watchouts
- Full metrics are not available yet for this ticker.
Annual data: 0 periods
Quarterly data: 6 periods
Stock snapshot: May 24, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BAYRY.
Grade F
0
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BAYRY Target | Bayer Ag Sponsored ADR | $26.9B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| BIIB | Biogen Inc. | $17.8B | 22.0x | 10.3x | 5.3% | -6.0% | 20.7% | N/A | N/A | N/A |
| GSK | GSK plc | $79.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| BMY | Bristol-Myers Squibb | $101.9B | 17.2x | 10.6x | 11.1% | 2.5% | 26.7% | N/A | N/A | N/A |
| GILD | Gilead Sciences | $128.0B | 19.8x | 15.4x | 17.9% | 3.6% | 32.1% | N/A | 1.7x | N/A |
| SNY | Sanofi Aventis | $133.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PFE | Pfizer Inc. | $135.4B | 19.0x | 14.8x | 9.0% | 8.5% | 14.5% | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
Financial Charts
No financial data available for BAYRY (annual).
1 superinvestors own BAYRY
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Kahn Brothers Group Kahn Brothers Group | 6,513,893 | $75M | 13.26% | 0.0% |